Drug Database · Clinicians

Ranitidine

Brands (48) Zentek, Contracid, Raniphil…Show all

H2 -receptor antagonist; H-2 receptor antagonist; and others PH FDA category

Rx · Prescription drugOTC · Over-the-counter57 PH productsPNF-listed
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID fcf27c99-8bd4-41fb-bff8-38fed9de76d9, version date September 24, 2026 (RANITIDINE · Atland Pharmaceuticals, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Short-term treatment of active duodenal ulcer.
  • Short-term treatment of active, benign gastric ulcers.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Ranitidine Tablets are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

No placebo – controlled comparative studies have been carried out for periods longer than 1 year. The treatment of pathological hypersecretory conditions. (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcers. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated.

Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets USP, 150 mg twice daily.

Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets USP, 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. ​​​​​​​Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.

Contraindications

CONTRAINDICATIONS Ranitidine Tablets are contraindicated for patients known to have hypersensitivity to the drug or any of the ingredients (see PRECAUTIONS).

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Active Duodenal Ulcer: The current recommended adult oral dosage of Ranitidine Tablets for duodenal ulcer is 150 mg twice daily. An alternative dosage of 300 mg once daily after the evening meal or at bedtime can be used for patients in whom dosing convenience is important. The advantages of one treatment regimen compared with the other in a particular patient population have yet to be demonstrated (see Clinical Trials: Active Duodenal Ulcer).

Smaller doses have been shown to be equally effective in inhibiting gastric acid secretion in US studies, and several foreign trials have shown that 100 mg twice daily is as effective as the 150 mg dose. Antacid should be given as needed for relief of pain (see CLINICAL PHARMACOLOGY: Pharmacokinetics). Maintenance of Healing of Duodenal Ulcers: The current recommended adult oral dosage is 150 mg at bedtime.

Pathological Hypersecretory Conditions (such as Zollinger - Ellison syndrome): The current recommended adult oral dosage is 150 mg twice daily. In some patients it may be necessary to administer Ranitidine Tablets USP, 150 mg doses more frequently. Dosages should be adjusted to individual patient needs and should continue as long as clinically indicated.

Dosages up to 6 g/day have been employed in patients with severe disease. Benign Gastric Ulcer: The current recommended adult oral dosage is 150 mg twice daily. Maintenance of Healing of Gastric Ulcers: The current recommended adult oral dosage is 150 mg at bedtime. GERD: The current recommended adult oral dosage is 150 mg twice daily.

Erosive Esophagitis: The current recommended adult oral dosage is 150 mg 4 times daily. Maintenance of Healing of Erosive Esophagitis: The current recommended adult oral dosage is 150 mg twice daily. Pediatric Use: The safety and effectiveness of Ranitidine Tablets have been established in the age group of 1 month to 16 years.

There is insufficient information about the pharmacokinetics of Ranitidine Tablets in neonatal patients (less than 1 month of age) to make dosing recommendations. The following 3 subsections provide dosing information for each of the pediatric indications. Treatment of Duodenal and Gastric Ulcers: The recommended oral dose for the treatment of active duodenal and gastric ulcers is 2 to 4 mg/kg twice daily to a maximum of 300 mg/day.

This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients. Maintenance of Healing of Duodenal and Gastric Ulcers: The recommended oral dose for the maintenance of healing of duodenal and gastric ulcers is to 2 to 4 mg/kg once daily to a maximum of 150 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.

Treatment of GERD and Erosive Esophagitis: Although limited data exist for these conditions in pediatric patients, published literature supports a dosage of 5 to 10 mg/kg/day, usually given as 2 divided doses. Dosage Adjustment for Patients with Impaired Renal Function: On the basis of experience with a group of subjects with severely impaired renal function treated with Ranitidine Tablets, the recommended dosage in patients with a creatinine clearance < 50 mL/min is 150 mg every 24 hours.

Should the patient’s condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating ranitidine. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis. Elderly patients are more likely to have decreased renal function, therefore caution should be exercised in dose selection, and it may be useful to monitor renal function.

(see CLINICAL PHARMACOLOGY: Pharmacokinetics: Geriatrics and PRECAUTIONS: Geriatric Use).

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration)

Patients with Impaired Renal Function: On the basis of experience with a group of subjects with severely impaired renal function treated with Ranitidine Tablets, the recommended dosage in patients with a creatinine clearance < 50 mL/min is 150 mg every 24 hours. Should the patient’s condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating ranitidine. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Film-coated tablet: 75 mg, 150 mg, 300 mg
  • ) solution for injection: 25 mg/mL (50 mg/2 mL
  • Solution for injection: 25 mg/mL, 25 mg/mL (50 mg/2 mL
  • Tablet: 75 mg, 150 mg, 300 mg
  • Sterile solution for injection: 50 mg/2 mL
  • ) sterile solution for injection: 25 mg/mL (50 mg/2 mL
  • ): 25 mg/mL (50 mg/2 mL

Registered products in the Philippines

57 products registered with the Food and Drug Administration (FDA) Philippines list Ranitidine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products57
Philippine FDA-registered products for Ranitidine
Package insert
AcilocRanitidine (as Hydrochloride)
25 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule in Blister Pack x 2 mL (Box of 5's)
Rx
Cadila Pharmaceuticals Ltd.India
Speed Cure PharmaImporter: Ambica International Corporation
DRP-869
Mar 12, 2029
AetinRanitidine (as hydrochloride)
50 mg/2 mL Sterile Solution for Injection (I.M./I.V.)Amber Ampoule x 2 mL (Box of 10's)
Rx
Umedica Laboratories Pvt. Ltd.India
Dynasty PharmaceuticalsImporter: Suhitas Pharmaceuticals Inc.
DRP-655-05
Sep 19, 2031
AlceraRanitidine (as hydrochloride)
300 mg Film-Coated TabletAlu/PVC Blister Pack x 4’s (Box of 100’s)
Rx
Hizon Laboratories, Inc.Philippines
—
DRP-4494
Mar 22, 2027
AlfluxRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Solution for Injection (IM/IV)Amber Glass Ampoule x 2 mL (Box of 10's)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Altomed Pharmaceuticals, Inc.Importer: Euro-Health Care Exponents, Inc.
DRP-7635
Nov 14, 2028
AmeketRanitidine (as hydrochloride)
25 mg/mL Solution for Injection (I.M./I.V.)Amber Ampoule x 2mL (Box of 10's)
Rx
SM Pharmaceutical (M) Sdn. Bhd.Malaysia
PNF Pharmaceutical, Inc.
DRP-8324
Jun 18, 2028
AmkodineRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) sterile solution for injection (IM/IV)USP type I amber glass ampoule x 2 mL box of 10's
Rx
Shandong Xier Kangtai Pharmaceuticals Co., Ltd.China
AMK Pharma International TradingImporter: JF Draf Pharmaceuticals Corporation
DRP-159-05
May 19, 2029
ContracidRanitidine (as hydrochloride)
150 mg TabletFoil Strip x 10’s (Box of 100’s)
Rx
Umedica Laboratories Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.
DRP-1237
Feb 2, 2029
ContracidRanitidine (as hydrochloride)
50 mg/2 mL Sterile Solution for Injection (I.M/I.V)Amber Ampoule x 2mL (Box of 10’s)
Rx
Umedica Laboratories Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.
DRP- 655
Oct 9, 2030
DartRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Solution for Injection (IM/IV)Clear Glass Ampoule in Plastic Tray x 10's (Box of 10's)
Rx
Medicaids Pakistan (Pvt.) Ltd.Pakistan
Sahar International Trading, Inc.
DRP-3608
Oct 27, 2030
DocranRanitidine
75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's)
OTC
Phil. United Pharma CorporationPhilippines
Trader: Docteur's Choice Corporation
DRP-10674
Nov 29, 2026
EastidineRanitidine (as Hydrochloride)
25 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule in Blister Pack x 2 mL (Box of 5's)
Rx
Cadila Pharmaceuticals Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-869-01
Mar 12, 2029
EntacRanitidine (as Hydrochloride)
25 mg/mL Solution for Injection (I.M./I.V.)USP Type I Amber Glass Ampoule x 2 mL (Box of 10's)
Rx
Neon Laboratories, Ltd.India
Elin Pharmaceuticals, Inc.
DR-XY29332
Jan 28, 2029
Eu-RanRanitidine (as hydrochloride)
150 mg TabletFoil Strip x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Euro-Health Care Exponents, Inc.
DR-XY34585
May 15, 2028
EurodinRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Solution for InjectionUSP Type I Amber Glass Ampoule x 2 mL (Box of 10's)
Rx
Shandong Xier Kangtai Pharmaceutical Co. LtdChina
Euro-Care Products PhilippinesImporter: JF Draf Corporation
DRP-159-10
May 19, 2029
Gastrosaph AB150Ranitidine (as Hydrochloride)
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's
Rx
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-4047
Oct 15, 2027
Gastrosaph AF300Ranitidine (as hydrochloride)
300 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 50's)
Rx
SAPPHIRE LIFESCIENCES PVT. LTDIndia
NELPA LIFESCIENCES, INC.
DRP-4477
Jun 14, 2028
HacidacRanitidine (as Hydrochloride)
25 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 2 mL in Blister Pack x 5's (Box of 5's)
Rx
Cadila Pharmaceuticals Ltd.India
Unitechnik Ventures CorporationImporter: Ambica International Corporation
DRP-869-02
Mar 12, 2029
HarlineRanitidine (as Hydrochloride)
150 mg Film-Coated TabletFoil Strip x 10's (Box of 100's)
Rx
Centurion Laboratories Pvt. Ltd.India
Harlem SalesImporter: Philgen Pharmaceuticals Inc.
DRP-1857-05
Dec 6, 2027
IldecefRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL Solution for Injection (IM/IV)Amber Glass Ampoule x 2 mL (Box of 10's)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Medirich Pharma Distribution Corp.Importer: Euro-Health Care Exponents, Inc.
DRP-7635-02
Nov 14, 2028
LoracidRanitidine (as Hydrochloride)
25 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule in Blister Pack x 2 mL (Box of 5's)
Rx
Cadila Pharmaceuticals Ltd.India
D&G PharmaImporter: Ambica International Corporation
DRP-869-03
Mar 12, 2029
MD-CIDRanitidine (as hydrochloride)
50 mg/2 mL Sterile Solution for Injection (I.M./I.V.)Amber Ampoule x 2 mL (Box of 10's)
Rx
Umedica Laboratories Pvt. Ltd.India
MDB Pharma TradingImporter: Suhitas Pharmaceuticals Inc.
DRP-655-06
Sep 11, 2031
NelstacRanitidine (as hydrochloride)
25 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 2 mL (Box of 10's)
Rx
Celogen Pharma Pvt. Ltd.India
Pharmastar Int'l Trading Corp.
DRP-7171
Feb 7, 2029
QualranRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Sterile Solution for InjectionUSP Type I Amber Glass Ampoule x 2 mL (Box of 10's)
Rx
Shandong Xier Kangtai Pharmaceutical Co. Ltd.China
Importer: JF Draf Pharmaceuticals Corp.
DRP-159
May 19, 2029
RanaeRanitidine (as hydrochloride)
150 mg TabletFoil Strip x 10’s Box of 100’s
Rx
Umedica Laboratories Pvt. Ltd.India
Starpharm, Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-1237-01
Feb 2, 2029
RanetinRanitidine (as Hydrochloride)
25 mg/mL Solution for Injection (IM/IV)2 mL USP Type I Amber Ampoule x 10 Ampoules per tray
Rx
Reyoung Pharmaceutical Co. Ltd.China
Philgen Pharmaceuticals Inc.
DRP-2017
May 24, 2027
RanicidRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I amber glass ampoule x 2 mL in plastic tray (Box of 10's)
Rx
Farbe FirmaIndia
Vitalis Pharma Phil. Corp.Importer: AMB HK Enterprises Inc.
DRP-12769-01
Oct 6, 2027
RanidenRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I amber glass ampoule x 2 mL in plastic tray (Box of 10's)
Rx
Farbe Firma Pvt. LtdIndia
Cyden Medicale Trading Inc.Importer: AMB HK Enteprises Inc.
DRP-12769-02
Oct 6, 2027
RanigerdRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Solution for Injection (I.M./I.V.)2 mL-net content USP Type I amber glass ampo plastic tray x 10's (Box of 10's)
Rx
Zee Laboratories LimitedIndia
Eon Pharmatek, Inc.
DR-XY48905
Oct 20, 2028
RanipenRanitidine (as hydrochloride)
25mg/mL (50mg/2mL)USP Type I Amber Glass Ampoule x 2mL Box of 10's
Rx
Shandong Xier Kangtai Pharmaceutical Co., Ltd.China
Planetarium Enterprise, Inc.Importer: JF Draf Pharmaceuticals Corp.
DRP-159-09
May 19, 2029
RanipharRanitidine (as hydrochloride)
25 mg/mL (50 mg/ 2mL) Solution for Injection (IM/IV)2mL USP Type I Amber Glass Ampoule (Box of 5's)
Rx
Scott-Edil Pharmacia LimitedIndia
Pharmakon Biotec Inc.
DRP-4088
Nov 8, 2027
RaniphilRanitidine (as hydrochloride)
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
Rx
Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.
DRP-7970
Apr 16, 2030
RaniphilRanitidine (as hydrochloride)
300 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
Rx
Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.
DRP-7973
Apr 16, 2030
RanipidRanitidine (as Hydrochloride)
50mg/2mL Sterile Solution for Injection (I.M/I.V)Amber Ampoule x 2mL (Box of 10’s)
Rx
Umedica Laboratories Pvt. Ltd.India
Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-655-07
Oct 9, 2030
RaniteinRanitidine (As Hydrochloride)
150 mg Film-Coated TabletFoil Strip x 10's (Box of 100's)
Rx
Centurion Laboratories Pvt. Ltd.India
Health Saver Pharma Inc.
DRP-1857
Dec 6, 2027
RaniteinRanitidine (As Hydrochloride)
300 mg Film-Coated TabletFoil Strip x 10's (Box of 100's)
Rx
Centurion Laboratories Pvt. Ltd.India
Health Saver Pharma Inc.
DRP-1851
Sep 14, 2027
RanitrisRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Solution for Injection (IM/IV)
Rx
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-17730
Feb 23, 2031
RanivicRanitidine (as hydrochloride)
25 mg/mL (50 mg/ 2mL) Solution for Injection (IM/IV)2mL USP Type I Amber Glass Ampoule (Box of 5's)
Rx
Scott-Edil Pharmacia LimitedIndia
Grovic Pharma Inc.Importer: Pharmakon Biotec Inc.
DRP-4088-01
Nov 8, 2027
RatidinRanitidine (as Hydrochloride)
150 mg Film-Coated TabletFoil Strip x 10's (Box of 100's)
Rx
Centurion Laboratories Pvt. Ltd.India
TGP Pharma, Inc.Importer: Philgen Pharmaceuticals Inc.
DRP-1857-01
Dec 6, 2027
RatidinRanitidine (as Hydrochloride)
300 mg Film-Coated TabletFoil Strip x 10's (Box of 100's)
Rx
Centurion Laboratories Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-1851-01
Sep 14, 2027
RaxideRanitidine (As Hydrochloride)
150 mg TabletAluminum Foil Strip X 4's (Box of 100's)
Rx
Hizon Laboratories, Inc.Philippines
Trader: Gx International, Inc.
DR-XY26358
Jun 21, 2031
RaxideRanitidine (As Hydrochloride)
300 mg Film-Coated TabletFoil Strip X 10's (Box of 30's)
Rx
Hizon Laboratories, Inc.Philippines
Trader: Gx International, Inc.
DR-XY30701
Mar 7, 2031
RaxidineRanitidine (As Hydrochloride)
25 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 2 mL (Box of 10's)
Rx
Harmann Pharmaceutical Laboratories (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DR-XY39368
May 3, 2031
UlcedrugRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Solution for Injection (IM/IV)Amber Glass Ampoule x 2 mL (Box of 10's)
Rx
BCWorld Pharm, Co., Ltd.Republic of Korea
Medhaus Pharma, IncorporatedImporter: Euro-Health Care Exponents, Inc.
DRP-7635-01
Nov 14, 2028
UlceptorRanitidine (as hydrochloride)
75 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Drugmaker's Laboratories, Inc.Philippines
Trader: Terramedic, Inc.
DR-XY34473
Apr 15, 2028
UlcerixRanitidine Hydrochloride
25 mg/mL Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 2 mL (Box of 10's)
Rx
Ciron Drugs & Pharmaceuticals Pvt., Ltd.India
Phil Pharmawealth Inc.Trader: Oboi Laboratories
DR-XY19524-B
Jan 23, 2030
Ulci-BlocRanitidine (as Hydrochloride)
150 mg Film-Coated TabletAlu-Alu Foil Strip x 10's (Box of 100's)
Rx
Bal Pharma Ltd.India
Endure Medical, Inc.Importer: Singapore Genebio, Inc.
DR-XY39564
Jun 6, 2027
UlzimRanitidine (as hydrochloride)
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Incorporated
DR-XY37456
Feb 10, 2030
UnbrandedRanitidine (as Hydrochloride)
150 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Drugmakers Laboratories, Inc.E and E Industrial Complex Brgy. San Antonio San Pedro Laguna
—
DRP-8156
Nov 23, 2031
UnbrandedRanitidine (as Hydrochloride)
75 mg TabletAlu/Clear Blister Pack x 20's (Box of 100's)
OTC
Drugmakers Laboratories IncPhilippines
—
DR-XY30153
Oct 19, 2031
ZantolRanitidine (as Hydrochloride)
25 mg/mL (50mg/2mL) Solution for Injection (I.M./I.V.)Type I Amber Glass Ampoule x 2 mL in blister tray (Box of 10’s)
Rx
Zhejiang Ruixin Pharmaceutical Co., Ltd.China
Global Pharmatrade
DR-XY40614
Sep 8, 2031
ZantricidRanitidine (as hydrochloride)
25 mg/mL (50 mg/2 mL) Sterile Solution for Injection (IM/IV)Amber Glass Ampoule x 2 mL Box of 10's
Rx
Shandong Xier Kangtai Pharmaceutical Co., Ltd.China
Charmmed IncorporatedImporter: JF Draf Pharmaceuticals Corp.
DRP-159-04
May 19, 2029
ZentekRanitidine (As Hydrochloride)
150mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14160
Jul 7, 2028
ZentekRanitidine (as hydrochloride)
25 mg/mL (50 mg/2mL) Solution For Injection (I.M./I.V.)USP Type 1 amber glass ampoule x 2 mL in plastic tray (Box of 10's)
Rx
Farbe FirmaIndia
AMB HK Enterprises Inc.
DRP-12769
Oct 6, 2027
ZentekRanitidine (As Hydrochloride)
300mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14159
Jul 7, 2028
Zidaxim 300Ranitidine (as hydrochloride)
300 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
Rx
Hexagon Pharmaceuticals ltd.India
Hexagon Pharmaceuticals
DRP-551
Nov 22, 2027
Zidaxim-150Ranitidine (as hydrochloride)
150 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DRP-550
Nov 7, 2029
ZilatecRanitidine
150 mg Film-Coated TabletAlu/Alu Foil Strip x 10’s (Box of 100’s); Alu/Alu Foil Strip x 10’s (Box of 200’s)
Rx
Brawn Laboratories LimitedIndia
Ambica International Corporation
DRP-4651
Sep 2, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

PRECAUTIONS General: Symptomatic response to therapy with Ranitidine Tablets does not preclude the presence of gastric malignancy. Since Ranitidine Tablets are excreted primarily by the kidney, dosage should be adjusted in patients with impaired renal function (see DOSAGE AND ADMINISTRATION). Caution should be observed in patients with hepatic dysfunction since Ranitidine Tablets are metabolized in the liver.

Rare reports suggest that Ranitidine Tablets may precipitate acute porphyric attacks in patients with acute porphyria. Ranitidine Tablets should therefore be avoided in patients with a history of acute porphyria. This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons.

Although the overall incidence of FD&C Yellow No 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity. Laboratory Tests: False-positive tests for urine protein with MULTISTIX ® may occur during therapy with Ranitidine Tablets, and therefore testing with sulfosalicylic acid is recommended.

Drug Interactions: Ranitidine has been reported to affect the bioavailability of other drugs through several different mechanisms such as competition for renal tubular secretion, alteration of gastric pH and inhibition of cytochrome P 450 enzymes. Procainamide: Ranitidine, a substrate of the renal organic cation transport system, may affect the clearance of other drugs eliminated by this route.

High doses of ranitidine (e.g., such as those used in the treatment of Zollinger-Ellison syndrome) have been shown to reduce the renal excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs. Although this interaction is unlikely to be clinically relevant at usual ranitidine doses, it may prudent to monitor for procainamide toxicity when administered with oral ranitidine at a dose exceeding 300 mg per day.

Warfarin: There have been reports of altered prothrombin time among patients on concomitant warfarin and ranitidine therapy. Due to the narrow therapeutic index, close monitoring of increased or decreased prothrombin time is recommended during concurrent treatment with ranitidine. Ranitidine may alter the absorption of drugs in which gastric pH is an important determinant of bio-availability.

This can result in either an increase in absorption (e.g., triazolam, midazolam, glipizide) or a decrease in absorption (e.g., ketoconazole, Atazanavir, delavirdine, gefitinib). Appropriate clinical monitoring is recommended. Atazanavir: Atazanavir absorption may be impaired based on known interactions with other agents that increase gastric pH.

Use with caution. See atazanavir label for specific recommendations. Delavirdine: Delavirdine absorption may be impaired based on known interactions with other agents that increase gastric pH. Chronic use of H 2 -receptor antagonists with delavirdine is not recommended. Gefitinib: Gefitinib exposure was reduced by 44% with the co-administration of ranitidine and sodium bicarbonate (dosed to maintain gastric pH above 5.0).

Use with caution. Glipizide: In diabetic patients, glipizide exposure was increased by 34% following a single 150 mg dose of oral ranitidine. Use appropriate clinical monitoring when initiating or discontinuing ranitidine. Ketoconazole: Oral ketoconazole exposure was reduced by up to 95% when oral ranitidine was co-administered in a regimen to maintain a gastric pH of 6 or above.

The degree of interaction with usual dose of ranitidine (150 mg twice daily) is unknown. Midazolam: Oral midazolam exposure in 5 healthy volunteers was increased by up to 65% when administered with oral ranitidine at a dose of 150 mg twice daily. However, in another interaction trial in 8 volunteers receiving IV midazolam, a 300 mg oral dose of ranitidine increased midazolam exposure by about 9%.

Monitor patients for excessive or prolonged sedation when ranitidine is co-administered with oral midazolam. Triazolam: Triazolam exposure in healthy volunteers was increased by approximately 30% when administered with oral ranitidine at a dose of 150 mg twice daily. Monitor patients for excessive or prolonged sedation. Carcinogenesis, Mutagenesis, and Impairment of Fertility: There was no indication of tumorigenic or carcinogenic effects in life-span studies in mice and rats at dosages up to 2,000 mg/kg/day.

Ranitidine was not mutagenic in standard bacterial tests (Salmonella, Escherichia coli) for mutagenecity at concentrations up to the maximum recommended for these assays. In a dominant lethal assay, a single oral dose of 1,000 mg/kg to male rats was without effect on the outcome of 2 matings per week for the next 9 weeks.

Information for Patients: Keep Ranitidine Tablets in the original container (bottle) and protect from moisture. After the first opening of the bottle, discard unused tablets after 3 months (90 days), or by the expiration date on the bottle, whichever is sooner. If more than one bottle is dispensed, open only one bottle at a time.

Store additional bottles without opening until needed for dosing. At the time of dosing, remove one tablet from the bottle. Immediately close the bottle, secure the cap, and keep the bottle tightly closed. Keep the desiccant in the bottle. Pregnancy: Teratogenic Effects: Reproduction studies have been performed in rats and rabbits at doses upto 160 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Ranitidine Tablets.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers: Ranitidine is secreted in human milk. Caution should be exercised when Ranitidine Tablets are administered to a nursing mother.

Pediatric Use: The safety and effectiveness of Ranitidine Tablets have been established in the age-group of 1 month to 16 years for the treatment of duodenal and gastric ulcers, gastroesophageal reflux disease and erosive esophagitis, and the maintenance of healed duodenal and gastric ulcer. Use of Ranitidine Tablets in this age group is supported by adequate and well-controlled studies in adults, as well as additional pharmacokinetic data in pediatric patients and an analysis of the published literature (see CLINICAL PHARMACOLOGY: Pediatrics and DOSAGE AND ADMINISTRATION: Pediatric Use).

Safety and effectiveness in pediatric patients for the treatment of pathological hypersecretory conditions or the maintenance of healing of erosive esophagitis have not been established. Safety and effectiveness in neonates (less than 1 month of age) have not been established (see CLINICAL PHARMACOLOGY: Pediatrics). Geriatric Use: Of the total number of subjects enrolled in US and foreign controlled clinical trials of oral formulations of ranitidine for which there were subgroup analyses, 4,197 were 65 and over, while 899 were 75 and over.

No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, caution should be exercised in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLGY: Pharmacokinetics: Geriatrics and DOSAGE AND ADMINISTRATION: Dosage Adjustment for Patients with Impaired Renal Function).

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The following have been reported as events in clinical trials or in the routine management of patients treated with Ranitidine Tablets. The relationship to therapy with Ranitidine Tablets has been unclear in many cases. Headache, sometimes severe, seems to be related to administration of Ranitidine Tablets.

Central Nervous System: Rarely, malaise, dizziness, somnolence, insomnia and vertigo. Rare cases of reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Rare cases of reversible blurred vision suggestive of a change in accommodation have been reported.

Rare reports of reversible involuntary motor disturbances have been received. Cardiovascular: As with other H 2 -blockers, rare reports of arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats. Gastrointestinal: Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain and rare reports of pancreatitis.

Hepatic: There have been occasional reports of hepatocellular, cholestatic, or mixed hepatitis, with or without jaundice. In such circumstances, ranitidine should be immediately discontinued. These events are usually reversible, but in rare circumstances death has occurred. Rare cases of hepatic failure have also been reported.

In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg intravenously 4 times daily for 7 days, and in 4 of 24 subjects receiving 50 mg intravenously 4 times daily for 5 days. Musculoskeletal: Rare reports of arthralgias and myalgias. Hematologic: Blood count changes (leukopenia, granulocytopenia, and thrombocytopenia) have occurred in few patients.

These were usually reversible. Rare cases of agranulocytosis, pancytopenia, sometimes with narrow hypoplasia, and aplastic anemia and exceedingly rare cases of acquired immune hemolytic anemia have been reported. Endocrine: Controlled studies in animals and man have shown no stimulation of any pituitary hormone by Ranitidine Tablets and no antiadrenogenic activity, and cimetidine-induced gynecomastia and impotence in hypersecretory patients have resolved when Ranitidine Tablets has been substituted.

However, occasional cases of impotence and loss of libido have been reported in male patients receiving Ranitidine Tablets, but the incidence did not differ from that in the general population. Rare cases of breast symptoms and conditions, including galactorrhea and gynecomastia, have been reported in both males and females.

Integumentary: Rash, including rare cases of erythema multiforme. Rare cases of alopecia and vasculitis. Respiratory: A large epidemiological study suggested an increased risk of developing pneumonia in current users of histamine-2-receptor antagonists (H 2 RAs) compared with patients who had stopped H 2 RA treatment, with an observed adjusted relative risk of 1.63 (95% CI, 1.07 – 2.48).

However, a causal relationship between use of H 2 RAs and pneumonia has not been established. Other: Rare cases of hypersensitivity reactions (e.g., bronchospasm, fever, rash, eosinophilia), anaphylaxis, angioneurotic edema, acute interstitial nephritis, and small increases in serum creatinine. To report SUSPECTED ADVERSE REACTIONS, contact Atland Pharmaceuticals, LLC at 1-833-757-0904 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate that there are minor, but clinically insignificant, alterations in ranitidine half-life, distribution, clearance, and bioavailability.

Excretion: The principal route of excretion is the urine, with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours.

Renal clearance is about 410 mL/min, indicating active tubular excretion.

The elimination half-life is 2.5 to 3 hours.

Four patients with clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min) administered 50 mg of ranitidine intravenously had an average plasma half-life of 4.8 hours, a ranitidine clearance of 29 mL/min, and a volume of distribution of 1.76 L/kg.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Ranitidine Tablets are a competitive, reversible inhibitor of the action of histamine at the histamine H 2 -receptors, including receptors on the gastric cells. Ranitidine Tablets do not lower serum Ca ++ in hypercalcemic states. Ranitidine Tablets are not an anticholinergic agent. Pharmacokinetics Absorption: Ranitidine Tablets are 50% absorbed after oral administration, compared to an intravenous (IV) injection with mean peak levels of 440 to 545 ng/mL occurring 2 to 3 hours after a 150 mg dose.

Absorption is not significantly impaired by the administration of food or antacids. Propantheline slightly delays and increases peak blood levels of ranitidine, probably by delaying gastric emptying and transit time. In one study, simultaneous administration of high-potency antacid (150 mmol) in fasting subjects has been reported to decrease the absorption of Ranitidine Tablets.

Distribution: The volume of distribution is about 1.4 L/kg. Serum protein binding averages 15%. Metabolism: In humans, the N-oxide is the principal metabolite in the urine; however, this amounts to <4% of the dose. Other metabolites are the S-oxide (1%) and the desmethyl ranitidine (1%). The remainder of the administered dose is found in the stool.

Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate that there are minor, but clinically insignificant, alterations in ranitidine half-life, distribution, clearance, and bioavailability. Excretion: The principal route of excretion is the urine, with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours.

Renal clearance is about 410 mL/min, indicating active tubular excretion. The elimination half-life is 2.5 to 3 hours. Four patients with clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min) administered 50 mg of ranitidine intravenously had an average plasma half-life of 4.8 hours, a ranitidine clearance of 29 mL/min, and a volume of distribution of 1.76 L/kg.

In general, these parameters appear to be altered in proportion to creatinine clearance (see DOSAGE AND ADMINISTRATION). Geriatrics: The plasma half-life is prolonged and total clearance is reduced in the elderly population due to a decrease in renal function. The elimination half-life is 3 to 4 hours. Peak levels average 526 ng/mL following a 150-mg twice-daily dose occur in about 3 hours (see PRECAUTIONS: Geriatric Use and DOSAGE AND ADMINISTRATION: Dosage Adjustment for Patients with Impaired Renal Function).

Pediatrics: There are no significant differences in the pharmacokinetic parameter values for ranitidine in pediatric patients (from one month up to 16 yrs of age) and healthy adults when correction is made for body weight. The average bioavailability of Ranitidine is given orally to pediatric patients is 48%, which is comparable to the bioavailability of Ranitidine in the adult population.

All other pharmacokinetic parameter values (t 1/2, Vd, and CL) are similar to those observed with intravenous Ranitidine use in pediatric patients. Estimates of C max and T max are displayed in Table 1. Table 1. Ranitidine Pharmacokinetics in Pediatric Patients Following Oral Dosing Population (age) n Dosage Form (dose) C max (ng/mL) T max​​​​​​​​​​​​​​​​​​​​​ (hours) Gastric or duodenal ulcer ​​​​​​​ (3.5 to 16 years) 12 Tablets (1 to 2 mg/ kg) 54 to 492 2.0 Plasma clearance measured in 2 neonatal patients (less than 1 month of age) was considerably lower (3 mL/min/kg) than children or adults and is likely due to reduced renal function observed in this population (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION: Pediatric use). ​​​​​​​​​​​​​​Pharmacodynamics: Serum concentrations necessary to inhibit 50% of stimulated gastric acid secretion are estimated to be 36 to 94 ng/mL.

Following a single oral dose of 150 mg, serum concentrations of Ranitidine are in this range up to 12 hours. However, blood levels bear no consistent relationship to dose or degree of acid inhibition. ​​​​​​​ Antisecretory Activity: Effects on Acid Secretion: Ranitidine Tablets inhibits both daytime and nocturnal basal gastric acid secretions as well as gastric acid secretion stimulated by food, betazole, and pentagastrin, as shown in below Table 2.

Table 2. Effect of Oral Ranitidine Tablets on Gastric Acid Secretion Time After Dose, hours % inhibition of Gastric Acid Output by Dose, mg 75 - 80 100 150 200 Basal Up to 4 99 95 Nocturnal Up to 13 95 96 92 Betazole Up to 3 97 99 Pentagastrin Up to 5 58 72 72 80 Meal Up to 3 73 79 95 It appears basal-, nocturnal-, and betazole- stimulated secretions are most sensitive to inhibition by Ranitidine Tablets, responding almost completely to doses of 100 mg or less, while pentagastrin- and food-stimulated secretions are more difficult to suppress.

Effects on other Gastrointestinal Secretions: Pepsin: Oral Ranitidine Tablets do not affect pepsin secretion. Total pepsin output is reduced in proportion to the decrease in volume of gastric juice. Intrinsic Factor: Oral Ranitidine Tablets have no significant effect on pentagastrin-stimulated intrinsic factor secretion.

Serum Gastrin: Ranitidine Tablets have little or no effect on fasting or postprandial serum gastrin. Other Pharmacologic Actions: Gastric bacterial flora-increase in nitrate-reducing organisms, significance not known. ​​​​​​​Prolactin levels-no effect in recommended oral or IV dosage, but small, transient, dose- related increases in serum prolactin have been reported after IV bolus injections of 100 mg or more.

Other pituitary hormones-no effect on serum gonadotropins, TSH or GH. Possible impairment of vasopressin release. No change in cortisol, aldosterone, androgen or estrogen levels. No antiandrogenic action. No effect on count, motility or morphology of sperm. Pediatrics: Oral doses of 6 to 10 mg/kg/day in 2 or 3 divided doses maintain gastric pH >4 throughout most of the dosing interval.

Clinical Trials​​​​​​​: Active Duodenal Ulcer: In a multicenter, double-blind, controlled, US study of endoscopically diagnosed duodenal ulcers, earlier healing was seen in patients treated with Ranitidine Tablets as shown in Table 3. Table 3. Duodenal Ulcer Patient Healing Rates ​​​​​​​​​​​​​​ Ranitidine Tablets * Placebo * Number Entered​​​​​​​ Healed/ Evaluable ​​​​​​​Number Entered Healed/ Evaluable Outpatients 195 69/182 (38%) ​​​​​​​​​​​​​​† 188 31/164 (19%) Week 2 Week 4 137/187 (73%) ​​​​​​​​​​​​​​† 76/168 (45%) * All patients were permitted antacids as needed for relief of pain ​​​​​​​ † ​​​​​​​ P < 0.0001 ​​​​​​In these studies, patients treated with Ranitidine Tablets reported a reduction in both daytime and nocturnal pain, and they also consumed less antacid than the placebo-treated patients.

Table 4. Mean Daily Doses of Antacid Ulcer Healed Ulcer Not Healed Ranitidine Tablets 0.06 0.71 Placebo 0.71 1.43 Foreign studies have shown that patients heal equally well with 150 mg twice daily and 300 mg at bedtime (85% versus 84%, respectively) during a usual 4-week course of therapy. If patients require extended therapy of 8 weeks, the healing rate may be higher for 150 mg twice daily as compared to 300 mg at bedtime (92% versus 87%, respectively).

Studies have been limited to short-term treatment of acute duodenal ulcer. Patients whose ulcers healed during therapy had recurrences of ulcers at the usual rates. Maintenance Therapy in Duodenal Ulcer: Ranitidine has been found to be effective as a maintenance therapy for patients, following healing of acute duodenal ulcers.

In 2 independent, double-blind, multi-center, controlled trials, the number of duodenal ulcers observed was significantly less in patients treated with Ranitidine Tablets (150 mg at bedtime) than in patients treated with placebo over a 12-month period. Table 5. Duodenal Ulcer Prevalence Double-Blind, Multicenter, Placebo-Controlled Trials Multicenter Trial Drug Duodenal Ulcer Prevalence No. of Patients 0-4 Months 0-8 Months 0-12 Months USA RAN 20% * 24%​​​​​​​ * 35% * 138 PLC 44% 54% 59% 139 Foreign RAN 12%​​​​​​​ * 21%​​​​​​​ * 28% * 174​​​​​​​ PLC 56% 64% 68% 165 % = Life table estimate. * = P < 0.05 (Ranitidine Tablets versus comparator).

RAN = ranitidine (Ranitidine Tablets) PLC = Placebo. As with other H 2 -antagonists, the factors responsible for the significant reduction in the prevalence of duodenal ulcers include prevention of recurrence of ulcers, more rapid healing of ulcers that may occur during maintenance therapy, or both. Gastric Ulcer: In a multicentre, double-blind, controlled, US study of endoscopically diagnosed gastric ulcers, earlier healing was seen in the patients treated with Ranitidine Tablets as shown in Table 6. ​​​​​​​ Table 6.

Gastric Ulcer Patient Healing Rates Ranitidine Tablets * Placebo * Number entered ​​​​​​​Healed / Evaluable Number entered Healed / Evaluable Outpatients 92 16/83 (19%) 94 10/83 (12%) Week 2 Week 4 50/73 (68%)​​​​​​​ † 35/69 (51%) * All patients were permitted antacids as needed for relief of pain. † P= 0.009 In this multicenter trial, significantly more patients treated with Ranitidine Tablets became pain free during therapy. Maintenance of Healing Gastric Ulcers: In 2 multicentre, double-blind, randomized, placebo-controlled, 12-month trials conducted in patients whose gastric ulcers had been previously healed, Ranitidine Tablets 150 mg at bed time was significantly more effective than placebo in maintaining healing of gastric ulcers.

Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome): Ranitidine Tablets inhibit gastric acid secretion and reduces occurrence of diarrhea, anorexia, and pain in patients with pathological hypersecretion associated with Zollinger-Ellison syndrome, systemic mastocytosis, and other pathological hypersecretory conditions. (eg. postoperative, “short-gut” syndrome, idiopathic).

Use of Ranitidine Tablets was followed by healing of ulcers in 8 of 19 (42%) patients who were intractable to previous therapy. Gastroesophageal Reflux Disease (GERD): In 2 multicenter, double-blind, placebo-controlled, 6-week trials performed in the United States and Europe, Ranitidine Tablets USP, 150 mg twice daily was more effective than placebo for the relief of heartburn and other symptoms associated with GERD.

Ranitidine-treated patients consumed significantly less antacid than did placebo-treated patients. The US trial indicated that Ranitidine Tablets USP, 150 mg twice daily significantly reduced the frequency of heartburn attacks and severity of heartburn pain within 1 to 2 weeks after starting therapy. The improvement was maintained throughout the 6-week trial period.

Moreover, patient response rates demonstrated that the effect of heartburn extends through both the day and nighttime periods. In 2 additional US multicenter, double-blind, placebo-controlled, 2-week trials, Ranitidine Tablets USP, 150 mg twice daily was shown to provide relief of heartburn pain within 24 hours of initiating therapy and a reduction in the frequency of severity of heartburn.

Erosive Esophagitis: In 2 multicenter, double-blind, randomized, placebo-controlled, 12- week trials performed in the United States, Ranitidine Tablets USP, 150 mg 4 times daily was significantly more effective than placebo in healing endoscopically diagnosed erosive esophagitis and in relieving associated heartburn. The erosive esophagitis healing rates were as follows in Table 7: Table 7.

Erosive Esophagitis Patient Healing Rates Healed/Evaluable Placebo * n=229 Ranitidine Tablets USP, 150 mg 4 times daily * n=215 Week 4 43/198 (22%) 96/206 (47%)​​​​​​​ † Week 8 63/176 (36%) 142/200 (71%)​​​​​​​ † Week 12 92/159 (58%) 162/192 (84%)​​​​​​​ † * All patients were permitted antacids as needed for relief of pain. † P < 0.001 versus placebo. No additional benefit in healing of esophagitis or in relief of heartburn was seen with a ranitidine dose of 300 mg 4 times daily.

Maintenance of Healing of Erosive Esophagitis: In 2 multicenter, double-blind, randomized, placebo-controlled, 48-week trials conducted in patients whose erosive esophagitis had been previously healed, Ranitidine Tablets USP, 150 mg twice daily was significantly more effective than placebo in maintaining healing of erosive esophagitis.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Ranitidine 25 mg/mL, 2 mL Ampule₱2.59–₱33.00Reference ₱3.28per ampuleDPRI procurement range
Ranitidine 150 mg Tablet₱0.59–₱0.88Reference ₱0.67per tabletDPRI procurement range
Ranitidine 300 mg Tablet₱2.05–₱3.80Reference ₱2.05per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Ranitidine (as hydrochloride)
PNF listingOral: 150 mg and 300 mg tablet
PNF listingOral: 75 mg/5 mL syrup, 60 mL and 150 mL
PNF listingInj.: 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. RANITIDINE · Atland Pharmaceuticals, LLC [US FDA-approved label, version 1, September 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcf27c99-8bd4-41fb-bff8-38fed9de76d9
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .